Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > REGULATORY
REGULATORY
- Topical Ketoprofen Contraindicated in Later Pregnancy: MHLW Safety Information
May 2, 2014
- Point-Based Calculations for Premiums Will Improve Predictability, Says Creator
May 1, 2014
- PAFSC’s Second Committee Backs Approval of Janssen, Sanofi Prostate Cancer Drugs
May 1, 2014
- PAFSC’s First Committee Recommends Approval for SGLT-2 Inhibitor Canaglu
April 30, 2014
- Kitasato Daiichi to Carry on with Delayed Quota in Flu Vaccine Project, but Slapped with Delinquency Charges
April 30, 2014
- Kaketsuken, Takeda Picked for Flu Vaccine Project to Fill BIKEN Quota
April 30, 2014
- MHLW Issues Notification Calling for Revision of Package Insert for Sanofi’s Benambax
April 30, 2014
- MHLW Bureaucrats Think Chuikyo Will Spurn Annual Drug Price Revisions, Again
April 28, 2014
- MHLW Should Present Its Own Proposal to Design Envisioned Mixed Care System: Panel Chair
April 28, 2014
- PMDA’s Preliminary Meetings, Face-to-Face Counseling Rise in FY2013
April 28, 2014
- Chuikyo Healthcare Provider Rep Vexed by Health Minister Proposal on Use of Drug Cost-Effective Assessment
April 25, 2014
- JMA Veep Nakagawa Fumes at Industry, Says “Application Lag” Elicited New Mixed Care Proposal
April 25, 2014
- Chuikyo Subcommittee OKs Point-Based Premium Calculation Method, Adoption Scheduled in May
April 24, 2014
- LDP Study Group to Call for Expansion of R&D Tax Credit System, Oppose Annual NHI Price Cuts
April 24, 2014
- PAFSC’s Second Committee to Discuss Janssen, Sanofi Prostate Cancer Drugs on April 30
April 23, 2014
- Public Knowledge-Based Applications Appropriate for Propranolol, Levonorgestrel: Panel
April 23, 2014
- Health Minister Wary about Annual Drug Price Cuts, but Aso, Amari Give Backing
April 23, 2014
- Min. Tamura Positive about Mixed Care Discussions with Govt Panel
April 22, 2014
- MHLW Eyes 2 Year Transition for Electronic Data Submissions for New Drugs, Biosimilars
April 21, 2014
- DPJ Member Nagatsuma Asks MHLW to Consider Criminal Complaint over SIGN Trial
April 18, 2014
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…